To include your compound in the COVID-19 Resource Center, submit it here.

Linagliptin: Phase III data

A meta-analysis of 8 double-blind Phase III trials in patients with Type II diabetes showed that once-daily linagliptin (n=3,319)

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE